Evidence map›Paper›PMID 34474172›Full record

SynthesisAutoimmunity reviews2022

Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis.

Anuraag Jena, Shubhra Mishra, Parakkal Deepak, Praveen Kumar-M, Aman Sharma, Yusuf I Patel, Nicholas A Kennedy, Alfred H J Kim, Vishal Sharma, Shaji Sebastian

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Autoimmunity reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 10 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 10 syntheses or guidelines pooled it, 202 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Pooled it
  6. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2022
    Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Article
  12. Article
  13. Review
  14. Article
  15. Cutaneous reactions to vaccination.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Anuraag JenaDepartment of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Shubhra MishraDepartment of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Parakkal DeepakInflammatory Bowel Diseases Center, Division of Gastroenterology,Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. Electronic address: deepak.parakkal@wustl.edu.
Praveen Kumar-MDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Aman SharmaClinical Immunology and Rheumatology Wing, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Yusuf I PatelDepartment of Rheumatology, Hull University Teaching Hospitals NHS Trust, Hull, UK. Electronic address: yusuf.patel9@nhs.net.
Nicholas A KennedyDepartment of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. Electronic address: nick.kennedy1@nhs.net.
Alfred H J KimDivision of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: akim@wustl.edu.
Vishal SharmaDepartment of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: sharma.vishal@pgimer.edu.in.
Shaji SebastianIBD Unit - Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK. Electronic address: shaji.sebastian4@nhs.net.
Post Graduate Institute of Medical Education and Research · INUniversity of Hull · GBWashington University in St. Louis · USRoyal Devon & Exeter NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe treatment for COVID-19 often utilizes immune-modulating drugs. These drugs are also used in immune mediated inflammatory diseases (IMIDs). We performed a systematic review about seroconversion after SARS-CoV-2 vaccination in patients with IMIDs and impact of various drugs on seroconversion rates.

methodsElectronic databases were searched to identify relevant studies reporting seroconversion rates following SARS-CoV-2 vaccination in IMIDs. We calculated the pooled seroconversion rates after a single or two doses of vaccination, pooled seroconversion rates in patients with specific IMIDs, and rates in patients on various drugs/drug classes.

resultsTwenty-five studies were included in the systematic review. The pooled seroconversion rates after two doses of mRNA vaccination were higher (83.1, 95%CI: 74.9-89.0, I

conclusionSeroconversion rates after SARS-CoV-2 vaccination are lower in patients with IMIDs. Certain therapies (anti-TNF, anti-integrin, anti-IL 17, anti-IL6, anti-12/23) do not impact seroconversion rates while others (anti-CD20, anti-CTLA-4) result in poorer responses.

Indexed as

COVID-19SARS-CoV-2COVID-19 VaccinesHumansTumor Necrosis Factor InhibitorsVaccinationCOVID-19 VaccinesTumor Necrosis Factor InhibitorsAdenoviral associatedCOVID-19ImmunizationInflammatory bowel diseaseRheumatoid arthritisSpondyloarthropathySystemic lupus erythematosusVasculitis

Identifiers

PMID34474172
PMCPMC8404391
OpenAlexW3198017567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.